![shutterstock_1221615613 [Converted]-01 (](https://static.wixstatic.com/media/82019c_600022a8e6da4d6383ae9d13827f1f67~mv2.png/v1/crop/x_913,y_5,w_1980,h_1647/fill/w_438,h_364,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1221615613%20%5BConverted%5D-01%20(.png)
.png){kind=logo}
CHILDREN WITH AUTISM
SPECTRUM DISORDERS (ASD)
Pilot Study
OUR ADVISORS
.png)
STEPHANY COX, PHD
Autism Advisor
Pediatric Neuropsychologist, UCSF
TAMAR MARITZ, MBA
CA Cannabis Market Advisor
VP Business Development, BDS Analytics
OUR VALUED SPONSORS
BONNI GOLDSTEIN, MD
Clinical Advisor
![shutterstock_1221615613 [Converted]-01 (](https://static.wixstatic.com/media/82019c_600022a8e6da4d6383ae9d13827f1f67~mv2.png/v1/crop/x_913,y_5,w_1980,h_1647/fill/w_453,h_376,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1221615613%20%5BConverted%5D-01%20(.png)
METHODOLOGY
![shutterstock_429937732 [Converted]-02.pn](https://static.wixstatic.com/media/82019c_81a1491c02e64579a926f7c31c023e5d~mv2.png/v1/fill/w_142,h_149,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_429937732%20%5BConverted%5D-02_pn.png)
1
PARTICIPANTS
-
Children diagnosed with ASD.
-
Currently using medical cannabis under HCP supervision.
-
Living in California (Los Angeles and San Francisco Bay Area).
PRIVACY
-
Children’s data privacy is protected by HIPAA-compliant protocols.
![shutterstock_429937732 [Converted]-03.pn](https://static.wixstatic.com/media/82019c_74072124f48e4d999739e0c2ef459eb5~mv2.png/v1/fill/w_132,h_134,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_429937732%20%5BConverted%5D-03_pn.png)
2
3
SAMPLES
-
ASD: Saliva collected from children pre- and post-consumption of regularly prescribed medical cannabis dosage.
-
Control: Saliva collected from age-matched neurotypical children.
ANALYSIS
-
Cannformatics’ proprietary platform identifies biomarkers that significantly changed pre- and post-consumption of medical cannabis.
-
Samples from neurotypical children are collected and analyzed to determine the biomarkers baseline for healthy physiological range.
![shutterstock_429937732 [Converted]-07.pn](https://static.wixstatic.com/media/82019c_cb64f306b37c4d999b739c531d2544b9~mv2.png/v1/fill/w_140,h_142,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_429937732%20%5BConverted%5D-07_pn.png)
4
![shutterstock_429937732 [Converted]-07.pn](https://static.wixstatic.com/media/82019c_ab1691da113140739a6b9397c32bf359~mv2.png/v1/fill/w_139,h_141,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_429937732%20%5BConverted%5D-07_pn.png)
5
REPORTS
-
Study participants will receive a report showing their individual changes in biomarkers related to ASD symptoms before and after medical cannabis consumption.
-
We will seek to publish the finding in a scientific peer-reviewed medical journal, across mainstream media and at Cannformatics.com.
OUR GOAL
To be a trusted resource for parents and health care professionals by providing data and insights to build an effective cannabis regimen for children with ASD.